Modelling the Impact of Antiretroviral Use in Resource-Poor Settings

Background The anticipated scale-up of antiretroviral therapy (ART) in high-prevalence, resource-constrained settings requires operational research to guide policy on the design of treatment programmes. Mathematical models can explore the potential impacts of various treatment strategies, including timing of treatment initiation and provision of laboratory monitoring facilities, to complement evidence from pilot programmes. Methods and Findings A deterministic model of HIV transmission incorporating ART and stratifying infection progression into stages was constructed. The impact of ART was evaluated for various scenarios and treatment strategies, with different levels of coverage, patient eligibility, and other parameter values. These strategies included the provision of laboratory facilities that perform CD4 counts and viral load testing, and the timing of the stage of infection at which treatment is initiated. In our analysis, unlimited ART provision initiated at late-stage infection (AIDS) increased prevalence of HIV infection. The effect of additionally treating pre-AIDS patients depended on the behaviour change of treated patients. Different coverage levels for ART do not affect benefits such as life-years gained per person-year of treatment and have minimal effect on infections averted when treating AIDS patients only. Scaling up treatment of pre-AIDS patients resulted in more infections being averted per person-year of treatment, but the absolute number of infections averted remained small. As coverage increased in the models, the emergence and risk of spread of drug resistance increased. Withdrawal of failing treatment (clinical resurgence of symptoms), immunologic (CD4 count decline), or virologic failure (viral rebound) increased the number of infected individuals who could benefit from ART, but effectiveness per person is compromised. Only withdrawal at a very early stage of treatment failure, soon after viral rebound, would have a substantial impact on emergence of drug resistance. Conclusions Our analysis found that ART cannot be seen as a direct transmission prevention measure, regardless of the degree of coverage. Counselling of patients to promote safe sexual practices is essential and must aim to effect long-term change. The chief aims of an ART programme, such as maximised number of patients treated or optimised treatment per patient, will determine which treatment strategy is most effective.

[1]  B. Masquelier,et al.  Characterization of nevirapine (NVP) resistance mutations and HIV type 1 subtype in women from Abidjan (Côte d'Ivoire) after NVP single-dose prophylaxis of HIV type 1 mother-to-child transmission. , 2005, AIDS research and human retroviruses.

[2]  L. Palombi,et al.  HIV/AIDS in Africa: treatment as a right and strategies for fair implementation. False assumptions on the basis of a minimalistic approach. , 2005, AIDS (London).

[3]  F. Goebel Immune Reconstitution Inflammatory Syndrome (IRIS)—Another New Disease Entity Following Treatment Initiation of HIV Infection , 2005, Infection.

[4]  David P. Wilson,et al.  Designing Equitable Antiretroviral Allocation Strategies in Resource-Constrained Countries , 2005, PLoS medicine.

[5]  J. Salomon,et al.  Integrating HIV Prevention and Treatment: From Slogans to Impact , 2005, PLoS medicine.

[6]  N. Hearst,et al.  Condom promotion for AIDS prevention in the developing world: is it working? , 2004, Studies in family planning.

[7]  J. Mukherjee,et al.  Tackling HIV in resource poor countries , 2003, BMJ : British Medical Journal.

[8]  T. Flanigan,et al.  The safety, tolerability and effectiveness of generic antiretroviral drug regimens for HIV-infected patients in south India , 2003, AIDS.

[9]  N. Livesley,et al.  Antiretroviral therapy in a primary care clinic in rural South Africa. , 2003, AIDS.

[10]  A. Calmy,et al.  Highly active antiretroviral therapy in resource-poor settings: the experience of Médecins Sans Frontières , 2003, AIDS.

[11]  Richard D Moore,et al.  Survival in an Urban HIV‐1 Clinic in the Era of Highly Active Antiretroviral Therapy: A 5‐Year Cohort Study , 2003, Journal of acquired immune deficiency syndromes.

[12]  Maria Deloria-Knoll,et al.  Survival Benefit of Initiating Antiretroviral Therapy in HIV-Infected Persons in Different CD4+ Cell Strata , 2003, Annals of Internal Medicine.

[13]  Kent J Weinhold,et al.  Prolonged CD4+ cell/virus load discordance during treatment with protease inhibitor-based highly active antiretroviral therapy: immune response and viral control. , 2003, The Journal of infectious diseases.

[14]  Evan Wood,et al.  Is there a baseline CD4 cell count that precludes a survival response to modern antiretroviral therapy? , 2003, AIDS.

[15]  Simon D W Frost,et al.  Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population. , 2003, The Journal of infectious diseases.

[16]  G. d’Ettorre,et al.  Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy , 2003, Journal of medical virology.

[17]  A. Karpas,et al.  Characterization of nef gene of HIV type 1 in highly active antiretroviral therapy treated AIDS patients with discordance between viral load and CD4+ T cell counts. , 2002, AIDS research and human retroviruses.

[18]  H. Gershengorn,et al.  Could widespread use of combination antiretroviral therapy eradicate HIV epidemics? , 2002, The Lancet. Infectious diseases.

[19]  Jonathan AC Sterne,et al.  Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies , 2002, The Lancet.

[20]  P. Weidle,et al.  Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance , 2002, The Lancet.

[21]  A. Harries,et al.  Preventing antiretroviral anarchy in sub-Saharan Africa , 2001, The Lancet.

[22]  P. Massip,et al.  Changes in Human Immunodeficiency Virus Type 1 Populations after Treatment Interruption in Patients Failing Antiretroviral Therapy , 2001, Journal of virology.

[23]  S. Kippax,et al.  Modelling the effect of combination antiretroviral treatments on HIV incidence , 2001, AIDS.

[24]  R. Selik,et al.  Survival after AIDS diagnosis in adolescents and adults during the treatment era, United States, 1984-1997. , 2001, JAMA.

[25]  R Hoh,et al.  Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. , 2001, The New England journal of medicine.

[26]  K. Hertogs,et al.  Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure , 2000, AIDS.

[27]  M. Boily,et al.  Complementary hypothesis concerning the community sexually transmitted disease mass treatment puzzle in Rakai, Uganda , 2000, AIDS.

[28]  Noah Kiwanuka,et al.  Mortality associated with HIV infection in rural Rakai District, Uganda , 2000, AIDS.

[29]  T. Quinn,et al.  Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. , 2000, The New England journal of medicine.

[30]  J. Gallant,et al.  Strategies for long-term success in the treatment of HIV infection. , 2000, JAMA.

[31]  R. Anderson,et al.  Both a ‘magic bullet’ and good aim are required to link public health interests and health care needs in HIV infection , 2000, Nature Medicine.

[32]  H. Gershengorn,et al.  A tale of two futures: HIV and antiretroviral therapy in San Francisco. , 2000, Science.

[33]  M A Wainberg,et al.  Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use , 2000, AIDS.

[34]  V. Calvez,et al.  Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team). , 2000, JAMA.

[35]  M. Hirsch,et al.  Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. , 2000, JAMA.

[36]  E. Rosenberg,et al.  Reduced antiretroviral drug susceptibility among patients with primary HIV infection. , 1999, JAMA.

[37]  Richard A. Loftus,et al.  HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. , 1999, AIDS.

[38]  P. Kissinger,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. , 1998, The New England journal of medicine.

[39]  G. Satten,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.

[40]  Alan S. Perelson,et al.  Decay characteristics of HIV-1-infected compartments during combination therapy , 1997, Nature.

[41]  Anne M Johnson,et al.  Assessing participation bias in a sexual behaviour survey: implications for measuring HIV risk , 1997, AIDS.

[42]  D. Weissman,et al.  Immunopathogenic Mechanisms of HIV Infection , 1996, Annals of Internal Medicine.

[43]  A. Lazzarin,et al.  Antiretroviral treatment of men infected with human immunodeficiency virus type 1 reduces the incidence of heterosexual transmission. Italian Study Group on HIV Heterosexual Transmission. , 1994, Archives of internal medicine.

[44]  Hadi Dowlatabadi,et al.  Sensitivity and Uncertainty Analysis of Complex Models of Disease Transmission: an HIV Model, as an Example , 1994 .

[45]  D. Ho,et al.  Increased viral burden and cytopathicity correlate temporally with CD4+ T-lymphocyte decline and clinical progression in human immunodeficiency virus type 1-infected individuals , 1993, Journal of virology.

[46]  M. Moroni Genotypic resistance tests for the management of patients with viro-immunological discordant response to highly active antiretroviral therapy. , 2003, Scandinavian Journal of Infectious Diseases. Supplementum.

[47]  J. Cleland,et al.  Reliability and validity of survey data on sexual behaviour. , 1994, Health transition review : the cultural, social, and behavioural determinants of health.